David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Science and Engineering Ethics 8 (3):429-442 (2002)
Conflicts of interest are common and exist in academia, government, and many industries, including pharmaceutical development. Medical journal editors and others have recently criticized “the pharmaceutical industry,” citing concerns over investigator access to data, approaches to analysis of clinical trial data, and publication practices. Merck & Co., Inc. is a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products, directly and through its joint ventures. Although part of its mission is to provide a superior rate of return to its investors, Merck does not believe this creates an irreconcilable conflict of interest, particularly in activities concerning clinical drug development. We employ rigorous scientific methods to design, conduct, analyze, and report results of clinical trials in the development of innovative drugs and vaccines, with a focus on meeting unmet medical needs and with an ethic that puts the interests of the patient first. This article describes Merck’s approaches to potential conflicts of interest in drug development, particularly with regard to clinical trials. We believe that proprietary interests of the Company can be respected while observing objectivity and transparency in communicating clinical research results. The standards for the review of manuscripts reporting such trials for peer-reviewed publication should be the same, whether they are from Merck or elsewhere.
|Keywords||conflict of interest pharmaceutical drug development publication data access bias investigator clinical research|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Boleslav Lichterman (2002). Conflict or Harmony? Clinical Research and the Medical Press in Russia. Science and Engineering Ethics 8 (3):383-386.
Thomas C. Jones (2005). A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care. Science and Engineering Ethics 11 (4):575-587.
Kristin Shrader-Frechette (2011). Climate Change, Nuclear Economics, and Conflicts of Interest. Science and Engineering Ethics 17 (1):75-107.
Arvo Tikk (2002). Conflict of Interest in Medical Research in Estonia. Science and Engineering Ethics 8 (3):317-318.
Jordan J. Cohen (2002). Managing Financial Conflicts of Interest in Clinical Research. Science and Engineering Ethics 8 (3):401-406.
Joel Lexchin (2012). Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. [REVIEW] Science and Engineering Ethics 18 (2):247-261.
Sharmon Sollitto, Sharona Hoffman, Maxwell J. Mehlman, Robert J. Lederman, Stuart J. Youngner & Michael M. Lederman (2003). Intrinsic Conflicts of Interest in Clinical Research: A Need for Disclosure. Kennedy Institute of Ethics Journal 13 (2):83-91.
Micahel F. Green, Stimulating the Development of Drug Treatments to Improve Cognition in Schizophrenia.
Arrigo Schieppati, Norberto Perico & Giuseppe Remuzzi (2002). Conflict of Interest as Seen From a Researcher's Perspective. Science and Engineering Ethics 8 (3):337-342.
Added to index2009-01-28
Total downloads12 ( #145,109 of 1,410,179 )
Recent downloads (6 months)1 ( #177,870 of 1,410,179 )
How can I increase my downloads?